65,437 trials
Pancreatic Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 3; 1; 0; 2 participants
Difficult Airway · Anesthesia; Functional
Primary: Airway Seal Pressure — 30; 30 cmH2O
Dementia
Primary: Decisional Conflict Scale — 1.65; 1.97 units on a scale
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Primary: Number of Participants With Best Disease Response as Determined by the Independent Response Review Panel (IRRP) — 37; 5; 32; 24 participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria — 36.4 percentage of participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) Until Cut-off Date 25 January 2011 — 54.4 percentage of participants
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…
Type 2 Diabetes Mellitus
Primary: Flow Mediated Dilation — 6.8; 5.5 percent change
Deep Partial Thickness Burn
Primary: Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound…
Heart Failure
Primary: Percent of Subjects With an Attempted Implant of the Chronicle ICD System Free From System-related Chronicle ICD Complications at 6-months Post-implant. — 90.5…
Myopia · Astigmatism
Primary: Overall Vision — 8.2; 7.5 Units on a scale
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs — 4; 50; 14; 2 participants
Type 2 Diabetes
Primary: Hemoglobin A1C — -0.39; -0.26 percent — p=0.079
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Skin Diseases, Bacterial
Primary: Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit — 162; 152 participants